Ken Griffin Rocket Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$17.6 - $25.88 $128,480 - $188,924	-7,300 Reduced 28.19%	18,600 $343,000
Q2 2024 Aug 14, 2024	BUY	$20.66 - $26.72 $272,712 - $352,704	13,200 Added 103.94%	25,900 $557,000
Q1 2024 May 15, 2024	SELL	$26.16 - $30.74 $298,224 - $350,436	-11,400 Reduced 47.3%	12,700 $342,000
Q4 2023 Feb 14, 2024	BUY	$16.78 - $31.94 $65,442 - $124,566	3,900 Added 19.31%	24,100 $722,000
Q3 2023 Nov 14, 2023	BUY	$15.07 - $24.05 $213,994 - $341,510	14,200 Added 236.67%	20,200 $413,000
Q2 2023 Aug 14, 2023	SELL	$16.59 - $23.6 $77,973 - $110,920	-4,700 Reduced 43.93%	6,000 $119,000
Q1 2023 May 15, 2023	SELL	$15.79 - $22.6 $115,267 - $164,980	-7,300 Reduced 40.56%	10,700 $183,000
Q4 2022 Feb 14, 2023	BUY	$15.5 - $22.76 $279,000 - $409,680	18,000 New	18,000 $352,000

209

93.2M

319K

70.3K

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $987M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.